Besides, BPC 157 therapy effects described in rats with bile duct cirrhosis and portal hypertension resulted in much less Ki-67- and alpha smooth muscle actin (-SMA) staining, counteracted disturbed cell proliferation and cytoskeletal structure in hepatic stellate cells, and showed a less disturbed collagen presentation, and thereby, less Mallory staining, and more hepatocytes where fewer had double nuclei[25]
During differentiation from PFG towards HBs, histone acetylation significantly increased at the liver regulatory elements mediated by histone acetyltransferase P300 (Xu et al., 2011)
All clinical trial data and research findings presented are sourced from peer-reviewed journals and are provided for educational reference only
Preclinical research in animal models provides robust evidence for BPC-157s capacity to accelerate healing of damaged tendons, ligaments, muscle, and bone, while also protecting against gastrointestinal and neural injury
Because they work through entirely different biological pathways, there is no mechanism conflict between the two therapies